Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Randomized, Open-Label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BRAF Wild-Type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
Multiple Cancer Types
Colon,
Rectal
III
Eng, Cathy
NCT06750094
VICC-DTGIT24167
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
Multiple Cancer Types
Bladder,
Colon,
Esophageal,
Gastric/Gastroesophageal,
Head/Neck,
Kidney (Renal Cell),
Lung,
Ovarian,
Pancreatic,
Urologic
I/II
Berlin, Jordan
NCT04895709
VICC-DTPHI23183
Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors.
Lung
Lung
Lung
II
Ramirez, Robert
NCT04665739
SWOGTHOA021901
Non-invasive, Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
Miscellaneous
Miscellaneous
Miscellaneous
Early I
Osmundson, Evan
NCT05996432
VICC-EDMDT23195
A Single Arm Phase 2 Trial of Atezolizumab with Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)
Breast
Breast
Breast
II
Abramson, Vandana
NCT04434040
VICCBRE2056
An Interventional, Phase 3, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Pf-08634404 in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Treatment-Nave Participants with Metastatic Colorectal Cancer
Colon
Colon
Colon
III
Eng, Cathy
NCT07222800
VICCGI25060
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of LYL314, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants with Aggressive B-Cell Non-Hodgkin Lymphoma
Lymphoma
Lymphoma
Lymphoma
I/II
Dholaria, Bhagirathbhai
NCT05826535
VICCCTT25034
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Neuro-Oncology
Neuro-Oncology
Neuro-Oncology
II
Mohler, Alexander
NCT05425004
VICC-ITNEU23261
Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)
Kidney (Renal Cell)
Kidney (Renal Cell)
Kidney (Renal Cell)
II
Rini, Brian
NCT05361720
VICCURO21103
Open-Label, Single-Arm Phase 2 Study of Nogapendekin Alfa Inbakicept, PD-L1 T-haNK, Bevacizumab and Randomized Phase 2b Study of Nogapendekin Alfa Inbakicept, Bevacizumab, and Tumor Treatment Fields with or without PD-L1 T-haNK in Participants with Recurrent or Progressive Glioblastoma
Neuro-Oncology
Neuro-Oncology
Neuro-Oncology
II
Merrell, Ryan
NCT06061809
VICC-DTNEU24006
